NYSE:MRKPharmaceuticals
Merck (MRK) Stock May Be 39% Below Fair Value Despite Cancer Trial Progress
Merck stock has delivered strong gains over the past few years, yet the valuation signals are split, as a Discounted Cash Flow (DCF) view points to a sizable gap to intrinsic value while market based multiples suggest the shares already carry a premium. That mix leaves investors weighing a low overall value score against an intrinsic value estimate that screens the stock as materially undervalued.
Over the past 5 years, Merck has returned 132.6%, which puts recent pricing on a very different...